These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 24060868)

  • 61. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.
    Silva T; Cortes Martins H; Coutinho R; Leitão E; Silva R; Pádua E
    J Med Virol; 2015 Sep; 87(9):1549-57. PubMed ID: 25940586
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1.
    Costa VD; Delvaux N; Brandão-Mello CE; Nunes EP; de Sousa PSF; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):700-706. PubMed ID: 30880098
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.
    Shimakami T; Welsch C; Yamane D; McGivern DR; Yi M; Zeuzem S; Lemon SM
    Gastroenterology; 2011 Feb; 140(2):667-75. PubMed ID: 21056040
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
    Zhou Y; Müh U; Hanzelka BL; Bartels DJ; Wei Y; Rao BG; Brennan DL; Tigges AM; Swenson L; Kwong AD; Lin C
    J Biol Chem; 2007 Aug; 282(31):22619-28. PubMed ID: 17556358
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies influence responsiveness to treatment with pegylated interferon plus ribavirin in HCV/HIV-coinfected patients.
    Aparicio E; Franco S; Parera M; Andrés C; Tural C; Clotet B; Martínez MA
    J Virol; 2011 Jun; 85(12):5961-9. PubMed ID: 21471227
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.
    Serre SB; Krarup HB; Bukh J; Gottwein JM
    J Virol; 2013 Dec; 87(23):12776-93. PubMed ID: 24049176
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.
    Liang Y; Ishida H; Lenz O; Lin TI; Nyanguile O; Simmen K; Pyles RB; Bourne N; Yi M; Li K; Lemon SM
    Gastroenterology; 2008 Nov; 135(5):1710-1718.e2. PubMed ID: 18725224
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Potency and resistance analysis of hepatitis C virus NS5B polymerase inhibitor BMS-791325 on all major genotypes.
    Liu M; Tuttle M; Gao M; Lemm JA
    Antimicrob Agents Chemother; 2014 Dec; 58(12):7416-23. PubMed ID: 25267677
    [TBL] [Abstract][Full Text] [Related]  

  • 70. NS4A protein as a marker of HCV history suggests that different HCV genotypes originally evolved from genotype 1b.
    Sarwar MT; Kausar H; Ijaz B; Ahmad W; Ansar M; Sumrin A; Ashfaq UA; Asad S; Gull S; Shahid I; Hassan S
    Virol J; 2011 Jun; 8():317. PubMed ID: 21696641
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
    Forestier N; Larrey D; Guyader D; Marcellin P; Rouzier R; Patat A; Smith P; Bradford W; Porter S; Blatt L; Seiwert SD; Zeuzem S
    J Hepatol; 2011 Jun; 54(6):1130-6. PubMed ID: 21145848
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.
    Jensen TB; Gottwein JM; Scheel TK; Hoegh AM; Eugen-Olsen J; Bukh J
    J Infect Dis; 2008 Dec; 198(12):1756-65. PubMed ID: 19032070
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.
    Gal-Tanamy M; Zemel R; Bachmatov L; Jangra RK; Shapira A; Villanueva RA; Yi M; Lemon SM; Benhar I; Tur-Kaspa R
    Antiviral Res; 2010 Oct; 88(1):95-106. PubMed ID: 20705106
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation.
    Madan V; Paul D; Lohmann V; Bartenschlager R
    Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951
    [TBL] [Abstract][Full Text] [Related]  

  • 76. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.
    Vidal LL; Soares MA; Santos AF
    J Viral Hepat; 2016 Nov; 23(11):840-849. PubMed ID: 26775769
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cross-genotypic interaction between hepatitis C virus NS3 protease domains and NS4A cofactors.
    Wright-Minogue J; Yao N; Zhang R; Butkiewicz NJ; Baroudy BM; Lau JY; Hong Z
    J Hepatol; 2000 Mar; 32(3):497-504. PubMed ID: 10735621
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Development of robust in vitro serine protease assay based on recombinant Pakistani HCV NS3-4A protease.
    Fatima K; Tahir M; Qadri I
    Virus Res; 2011 Sep; 160(1-2):230-7. PubMed ID: 21756947
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy.
    Ndjomou J; Corby MJ; Sweeney NL; Hanson AM; Aydin C; Ali A; Schiffer CA; Li K; Frankowski KJ; Schoenen FJ; Frick DN
    ACS Chem Biol; 2015 Aug; 10(8):1887-96. PubMed ID: 25961497
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B
    J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.